The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate Carcinoma

Journal of Immunotherapy

Volumn 19, Issue 6, 1996, Pages 419-427

  Prewett, Marie ^a   Rockwell, Patricia ^a   Rockwell, R F ^b   Giorgio, Nicholas A ^a   Mendelsohn, John ^c,d,e   Scher, Howard I ^c,d   Goldstein, Neil I ^a  

^a ELI LILLY AND COMPANY   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

C225; EGFR; Monoclonal antibody; Prostatic carcinoma; Xenografts

Indexed keywords

CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CORRELATION FUNCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; CARCINOMA; HUMANS; IMMUNIZATION, PASSIVE; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0030324626     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199611000-00006     Document Type: Article

References (41)

1. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
2. Modjtahedi H, Dean C. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer [Review]. Int J Oncol 1994;4:277-96.
3. Kim HH, Sierke SL, Koland JG. Epidermal growth factor-dependent association of phosphatidylinositol-3-kinase with the erbB-3 gene product. J Biol Chem 1994;269:24747-55.
4. Plowman GD, Whitney GS, Neubauer MG, Green JM, McDonald VL, Todaro GJ, Shoyab M. Molecular cloning and expression of an additional epidermal growth factor related gene. Proc Natl Acad Sci USA 1990;87:4905-9.
5. Gullick WJ. Relevance of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991;47: 87-96.
6. Hartmann L, Ingle JN, Wold LE, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Cancer 1994;74:2956-63.
7. Jardines L, Weiss M, Fowble B, Greene M. Neu (c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 1993;61:268-82.
8. Cohen DW, Simak R, Fair WR, Melamed J, Scher HI, Cordon-Cardo C. Expression of transforming growth factor-α and the epidermal growth factor receptor in human prostate tissues. J Urol 1994;152:2120-4.
9. Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985;1:366-8.
10. Sainsbury JRC, Farndon JR, Sherbert GV, Harris AR. Epidermal-growth factor receptors and oestrogen receptors in human breast cancer. Lancet 1985;1:364-6.
11. Ethier S. Growth factor synthesis and human breast cancer progression. J Natl Cancer Inst 1995;87:964-73.
12. Perez-Soler R, Donato NJ, Shin DM, et al. Tumor epidermal growth factor receptor studies in patients with non-small lung carcinoma or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 1994;12:730-9.
13. Ware JL. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev 1993;12:287-301.
14. Traish AM, Wotiz HH. Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology 1987;121: 1461-7.
15. Maygarden SJ, Strom S, Ware JL. Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia. Arch Pathol Lab Med 1992;116:269-73.
16. Ibrahim GK, Kerns BJ, MacDonald JA, et al. Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J Urol 1993;149:170-3.
17. Scher HI, Sarkis A, Reuter V, et al. The changing pattern of expression of the epidermal growth factor receptor and transforming growth factor-α in the progression of prostatic neoplasms. Clin Cancer Res 1995;1:545-50.
18. Modjtahedi H, Eccles S, Sandle J, Box G, Titley J, Dean C. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res 1994;54:1695-701.
19. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995;95:1897-905.
20. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato JH. Biological effects in vitro of Mabs to human EGF receptors. Mol Biol Med 1983;1:511-4.
21. Kawamoto T, Sato JD, Polifoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by EGF: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 1983;80:1337-41.
22. Fan Z, Masui H, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monoclonal fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1983;53:4322-8.
23. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by antiepidermal growth factor receptor monoclonal antibodies. Cancer Res 1984;44:1002-7.
24. Masui H, Moroyama T, Mendelsohn J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res 1984;46: 5592-8.
25. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327-33.
26. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 xenografts. Cancer Res 1993;53:4637-42.
27. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994;15:42-52.
28. Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium-111 labeled anti-EGF receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991;83:97-104.
29. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-8.
30. Gill GN, Lazar CS. Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature 1981; 293:305-7.
31. Van der Vijver MJ, Kumar R, Mendelsohn J. Ligand-induced activation of A431 epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J Biol Chem 1991;266:7503-8.
32. Rockwell P, Goldstein NI. Role of protein tyrosine kinase receptors in cancer: possibilities for therapeutic intervention. Mol Cell Differ 1995;3:315-35.
33. Prewett M, Rockwell P, Rose C, Goldstein NI. Anti-tumor and cell cycle responses in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin. Int J Oncol 1996;9:217-24.
34. Altomonte N, Gloghini A, Bertola G, et al. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res 1993;53:3343-8.
35. Telford WG, King LE, Fraker PJ. Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry 1992;13: 137-43.
36. Rockwell P, Neufeld G, Glassman A, Caron D, Goldstein N. In vitro neutralization of vascular endothelial growth factor activation of flk-1 by a monoclonal antibody. Mol Cell Differ 1995;3:91-109.
37. Pretlow TG, Delmoro CM, Dilley GG, Spadafora CG, Pretlow TP. Transplantation of human prostatic carcinomas into nude mice in matrigel. Cancer Res 1991;51:3814-7.
38. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor α. Cancer Res 1991;51:2780-5.
39. Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ, Ware JL. Tumorgenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int J Cancer 1994;58:721-9.
40. Prewett M, Rockwell P, Rose C, Zuklys K, Goldstein NI. Altered cell cycle distribution and cyclin-cdk expression in A431 epidermoid carcinoma cells treated with doxorubicin and a chimeric monoclonal antibody to the epidermal growth factor receptor. Mol Cell Differ 1996;4:167-86.
41. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 1988;80:1605-11.